Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 7Completed 6Active not recruiting 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 36Thoracic 3Head & Neck 2Genitourinary 2Sarcoma 1Gynecologic 1Dermatologic 1CNS 1Breast 1

Conditions

Ovarian Neoplasms 368Uterine Cervical Neoplasms 144Carcinoma, Ovarian Epithelial 108Fallopian Tube Neoplasms 105Endometrial Neoplasms 99Breast Neoplasms 82Carcinoma, Non-Small-Cell Lung 70Neoplasms 55Stomach Neoplasms 49Melanoma 44Colorectal Neoplasms 44Neoplasm Metastasis 40Pancreatic Neoplasms 37Carcinoma, Renal Cell 36Triple Negative Breast Neoplasms 33Recurrence 31Squamous Cell Carcinoma of Head and Neck 28Lung Neoplasms 28Uterine Neoplasms 25Sarcoma 25Urinary Bladder Neoplasms 24Peritoneal Neoplasms 24Uterine Cervical Dysplasia 23Prostatic Neoplasms 23Colonic Neoplasms 23Esophageal Neoplasms 22Head and Neck Neoplasms 21Carcinoma, Transitional Cell 18Testicular Neoplasms 16Small Cell Lung Carcinoma 16

Interventions

ribociclib 1Fulvestrant 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Adenocarcinoma Of Esophagus × Gynecologic × Clear all
NCT05252416 2025-11-28

(VELA) Study of BLU-222 in Advanced Solid Tumors

Blueprint Medicines Corporation

Phase 1 Terminated
50 enrolled
GastrointestinalGynecologicSarcoma

Adenocarcinoma Of Esophagus, Carcinosarcoma, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡